IDEAS home Printed from https://ideas.repec.org/p/liu/liucec/234.html
   My bibliography  Save this paper

Shifting the risk in pricing and reimbursement schemes. A new model of risk-sharing agreements for innovative drugs

Author

Abstract

Risk sharing is becoming increasingly an increasingly popular instrument to regulate the price of new drugs. In the recent past, forms of risk-sharing agreements between the public regulator and the industry have been proposed and implemented, but their effects on price and profits are still controversial. Methods: We develop a model aimed at studying the effects on price and expected pro.t of several risk-sharing agreement between a regulator and the industry, based on the ex post effectiveness of the drug. We assume that the probability of being listed depends on the relative performance of the new drug in terms of effectiveness and budget required. The price is set according to the declared effcacy of the new drug, but if ex post the effectiveness falls short of what declared, several forms of penalties may be used by the regulator. Results: We show that the number of patients that are treated is not necessarily affected by risk-sharing/risk-shifting mechanisms; the price for which the drug is listed may be higher than without risk-sharing, but the expected profit of the industry is: a) always lower for risk-shifting schemes; b) for true risk-sharing it depends on the bargaining power of the company. Conclusions. Our model shows the difference between risk-sharing and risk shifting. The .rst mechanism could be used by the regulator to reduce uncertainty while the second is used to reduce the expected price of the drug. In the presence of risk sharing the listing price is not a good proxy for value for money.

Suggested Citation

  • Stefano Capri & Rossella Levaggi, 2010. "Shifting the risk in pricing and reimbursement schemes. A new model of risk-sharing agreements for innovative drugs," LIUC Papers in Economics 234, Cattaneo University (LIUC).
  • Handle: RePEc:liu:liucec:234
    as

    Download full text from publisher

    File URL: http://www.biblio.liuc.it/liucpap/pdf/234.pdf
    Download Restriction: no

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:liu:liucec:234. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Laura Ballestra). General contact details of provider: http://edirc.repec.org/data/liuccit.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.